Class summary at a glance.

Every drug in the Interleukin-23 Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 4tracked in Part D
CY24 Part D spend: $5.78Bcombined across class
Total Rx claims: 304K111K unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Risankizumab-Rzaa

Brand: Skyrizi · 218K Part D claims (CY24) · 84K beneficiaries · First FDA approval: 2021-04-26

Brand-only (no generics) 1212 plans require PA

Low NADAC$9679.49

→

Avg plan cost$18476.52

Part D spend $4.58B 2× spread, current vs floor

Class share

79%

of class CY24 spend

View profile →

Guselkumab

Brand: TREMFYA · 82K Part D claims (CY24) · 26K beneficiaries · First FDA approval: 2017-07-13

Brand-only (no generics) 1340 plans require PA

Low NADAC$7349.67

→

Avg plan cost$12295.24

Part D spend $1.13B 2× spread, current vs floor

Class share

20%

of class CY24 spend

View profile →

Tildrakizumab-Asmn

Brand: ILUMYA · 3K Part D claims (CY24) · 1K beneficiaries · First FDA approval: 2018-08-06

Brand-only (no generics) 14 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $57.1M

Class share

of class CY24 spend

View profile →

Mirikizumab-Mrkz

Brand: Omvoh · 995 Part D claims (CY24) · 263 beneficiaries · First FDA approval: 2023-10-26

Brand-only (no generics) 6 plans require PA Discontinued

Low NADAC—

→

Avg plan cost—

Part D spend $11.0M

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.